stockrowTalphera, Inc.
TLPH Healthcare Drug Manufacturers Specialty & Generic
Talphera, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $28,000.00, down 95.7% from fiscal 2023.
- Revenue
- −99.6%
- EPS
- +40.0%
- Free cash flow
- −33.1%
Quarter to June 2026, against a year earlier
Follow TLPH
Alert me
Talphera, Inc. (TLPH) EV/Sales
As of 5 November 2026, Talphera, Inc. (TLPH) trades at a EV/Sales of 156×. Over the past ten years it has ranged from −4.6× (March 2023) to 235× (August 2026); the current reading is higher than 97% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.9× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 80.6× | 583.08% |
| FY2023 | 11.8× | 418.56% |
| FY2022 | 2.3× | (81.31%) |
| FY2021 | 12.2× | (22.19%) |
| FY2020 | 15.6× | (71.61%) |
| FY2019 | 55.1× | 187.57% |
| FY2018 | 19.2× | 179.77% |
| FY2017 | 6.8× | 109.26% |
| FY2016 | 3.3× | (19.21%) |
| FY2015 | 4.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2025 | 51.6× | 147.82% |
| Mar 2025 | 20.8× | 76.36% |
| Dec 2023 | 11.8× | 509.00% |
| Sep 2023 | 1.9× | (72.33%) |
| 33 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IXHL Incannex Healthcare Inc. compare | −24.1× |
| ZYBT Zhengye Biotechnology Holding Limited compare | n/m |
| CTOR Citius Oncology, Inc. compare | n/m |
| RMTI Rockwell Medical, Inc. compare | 0.2× |
| ORGO Organogenesis compare | 0.3× |
| SCYX SCYNEXIS, Inc. compare | 0.5× |
| INCR InterCure Ltd. compare | 0.6× |
| CPIX Cumberland Pharmaceuticals Inc. compare | 2.6× |
| TLPH Talphera, Inc. | 156× |
| Drug Manufacturers Specialty & Generic industry median | 2.9× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)